Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked Immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve

Journal of Infectious Diseases

Volumn 210, Issue 10, 2014, Pages 1573-1581

  Gilbert, Peter B ^a   Gabriel, Erin E ^c   Miao, Xiaopeng ^d   Li, Xiaoming ^b   Su, Shu Chih ^e   Parrino, Janie ^e   Chan, Ivan S F ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Gilead Sciences   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d BIOGEN   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

causal inference; correlate of immunity; immune correlate of protection; principal stratification; signature of protection; statistical analysis; surrogate endpoint; vaccine efficacy trial

Indexed keywords

BIOLOGICAL MARKER; PLACEBO; VARICELLA ZOSTER VACCINE; VIRUS GLYCOPROTEIN; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MIDDLE AGED; NONHUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PREDICTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; SINGLE DRUG DOSE; VARICELLA ZOSTER VIRUS; VIRUS IDENTIFICATION; BLOOD; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MALE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MIDDLE AGED;

EID: 84912118654     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu279     Document Type: Article

References (41)

1. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340-6.
2. Katz J, Cooper EM,Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39:342-8.
3. Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23:490-6.
4. Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010; 8:37.
5. Hempenstall K, Nurmikko TJ, Johnson RW, AHern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2:e164.
6. Hope-Simpson RE. The nature of herpes zoster: A long-term study and a new hypothesis. Proc R Soc Med 1965; 58:9-20.
7. Mullooly JP, Riedlinger K, Chun C,Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005; 133:245-53.
8. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341-9.
9. Kost RG, Straus SE. Postherpetic neuralgia-pathogenesis, treatment, and prevention. N Engl J Med 1996; 335:32-42.
10. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44(suppl 1):S1-26.
11. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
12. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8.
13. Hammond O, Wang Y, Green T, et al. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J Med Virol 2006; 78:1679-87.
14. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35.
15. Levin MJ, Schmader KE, Gnann JW, et al. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis 2013; 208:1386-90.
16. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007; 196:1304-12.
17. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20:63-75.
18. Plotkin SA. Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-9.
19. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-65.
20. Clements-Mann ML. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses 1998; 14(suppl 3): S197-203.
21. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54:1615-7.
22. Chan ISF, Wang WWB, Heyse J. Vaccine clinical trials. encyclopedia of biopharmaceutical statistics, 3rd ed. New York: Dekker, 2010.
23. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40.
24. Kohberger RC, Jemiolo D, Noriega F. Prediction of pertussis vaccine efficacy using a correlates of protection model. Vaccine 2008; 26: 3516-21.
25. Gilbert PB, Qin L, Self SG. Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med 2008; 27:4758-78.
26. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics 2002; 58:21-9.
27. Gilbert PB, Hudgens MG. Evaluating candidate principal surrogate endpoints. Biometrics 2008; 64:1146-54.
28. Follmann D. Augmented designs to assess immune response in vaccine trials. Biometrics 2006; 62:1161-9.
29. Huang Y, Gilbert PB, Wolfson J. Design and estimation for evaluating principal surrogate markers in vaccine trials. Biometrics 2013; 69: 301-9.
30. Qin L, Gilbert PB, Follmann D, Li D. Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model. Ann Appl Stat 2008; 2:386-407.
31. Wolfson J, Gilbert PB. Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials. Biometrics 2010; 66:1153-61.
32. Miao X, Li X, Gilbert PB, Chan ISF. A multiple imputation approach for surrogate marker evaluation in the principal stratification causal inference framework. In: Lee M-L, Mitchell G, Satten G, Cai T, Pfeiffer R, Gandy A, eds. Risk assessment and evaluation of predictions, London: Springer, 2013.
33. Prentice RL. On the design of synthetic case-control studies. Biometrics 1986; 42:301-10.
34. Gilbert PB, Hudgens MG, Wolfson J. Commentary on Principal stratification - a goal or a tool? by Judea Pearl. Int J Biostat 2011; 7(1): Article 36.
35. Gabriel EE, Gilbert PB. Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy. Biostatistics 2014; 15:251-65.
36. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley, 1987.
37. Huang Y, Gilbert PB. Comparing biomarkers as principal surrogate endpoints. Biometrics 2011; 67:1442-51.
38. Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992; 166:253-9.
39. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188:1336-44.
40. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virusspecific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200:1068-77.
41. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection- serum bactericidal antibody activity. Vaccine 2005; 23:2222-7.